SLP:NSD-Simulations Plus, Inc (USD)

COMMON STOCK | Health Information Services | NSD

Last Closing Price

USD 38.81

Change

0.00 (0.00)%

Market Cap

USD 0.70B

Volume

0.22M

Average Target Price

USD 40.00 (+3.07%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers MedChem Studio, a software tool for data mining and designing new molecules; KIWI, a cloud-based Web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; and RENAsym for investigating and predicting drug-induced or acute kidney injury. Further, the company provides population modeling and simulation contract research services for the pharmaceutical and biotechnology industries; and clinical-pharmacology-based consulting services in support of regulatory submissions. It sells its pharmaceutical/chemistry software to pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies. The company was founded in 1996 and is headquartered in Lancaster, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-02-22 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CERN Cerner Corporation

N/A

USD23.73B 46.10 21.25
TXG 10x Genomics, Inc

N/A

USD7.89B N/A -333.94
HQY HealthEquity, Inc

N/A

USD6.22B 109.94 55.31
OMCL Omnicell, Inc

N/A

USD3.70B 61.63 28.47
INOV Inovalon Holdings, Inc

N/A

USD3.15B 406.80 22.87
PGNY Progyny, Inc

N/A

USD2.44B N/A 500.89
PINC Premier, Inc

N/A

USD2.23B 24.55 4.14
HMSY HMS Holdings Corp

N/A

USD2.13B 21.09 14.71
CHNG Change Healthcare Inc

N/A

USD2.01B N/A 0.00
RCM R1 RCM Inc

N/A

USD1.57B 5.90 17.35

ETFs Containing SLP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 33.51% 86% B 91% A-
Dividend Return 0.21% 50% F 9% F
Total Return 33.71% 86% B 91% A-
Trailing 12 Months  
Capital Gain 81.69% 91% A- 92% A-
Dividend Return 1.12% 50% F 23% F
Total Return 82.82% 91% A- 92% A-
Trailing 5 Years  
Capital Gain 518.98% 87% B+ 97% A+
Dividend Return 17.54% 100% A+ 71% C-
Total Return 536.52% 87% B+ 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 44.23% 76% C 92% A-
Dividend Return 2.02% 60% D- 55% F
Total Return 46.25% 76% C 93% A
Risk Return Profile  
Volatility (Standard Deviation) 28.94% 57% F 48% F
Risk Adjusted Return 159.85% 100% A+ 99% A+
Market Capitalization 0.70B 39% F 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 77.62 28% F 15% F
Price/Book Ratio 17.45 15% F 7% F
Price / Cash Flow Ratio 60.33 22% F 5% F
EV/EBITDA 49.02 21% F 5% F
Management Effectiveness  
Return on Equity 25.47% 100% A+ 93% A
Return on Invested Capital 24.93% 100% A+ 91% A-
Return on Assets 15.72% 100% A+ 98% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.25 41% F 21% F
Short Percent 11.16% 35% F 29% F
Beta -0.47 96% A 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

STA Verdict Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.